MicroRNAs in cardiometabolic disease

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Defects in homeostatic regulation of cholesterol and fatty acids are associated with major cardiometabolic risk factors that are prevalent in type 2 diabetes and atherosclerotic cardiovascular disease. Regulatory input is found at many levels; however, recent findings have revealed pivotal roles for small non-coding RNAs (microRNAs) of the endogenous RNA interference pathway in post-transcriptional control of major regulatory mechanisms underpinning cholesterol and energy homeostasis. In addition, aberrant expression of microRNAs has been implicated in marked pathophysiologic events contributing to the progression and development of atherosclerosis, including loss of endothelial integrity, vascular smooth muscle cell proliferation, neointimal hyperplasia, and foam cell formation. This review surveys the impact of microRNA-mediated regulation in biological processes governing the cholesterol/lipoprotein metabolism, fatty acid β-oxidation (eg by miR-122 and miR-33), and endothelial dysfunction related to atherosclerosis. Given the current advances in microRNA-based technologies, the clinical potential of microRNAs as novel therapeutic targets is highlighted as new alternative strategies to ameliorate cardiometabolic diseases.

Original languageEnglish
Pages (from-to)202-207
Number of pages6
JournalCurrent Atherosclerosis Reports
Volume13
Issue number3
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

MicroRNAs
Atherosclerosis
Fatty Acids
Cholesterol
Biological Phenomena
Small Untranslated RNA
Foam Cells
RNA Interference
Vascular Smooth Muscle
Type 2 Diabetes Mellitus
Smooth Muscle Myocytes
Hyperplasia
Homeostasis
Cardiovascular Diseases
Cell Proliferation
Technology
Therapeutics

Keywords

  • Atherosclerosis
  • Cholesterol
  • Fatty acids
  • Metabolism
  • microRNAs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

MicroRNAs in cardiometabolic disease. / Najafi, Hani.

In: Current Atherosclerosis Reports, Vol. 13, No. 3, 06.2011, p. 202-207.

Research output: Contribution to journalReview article

@article{8cf249ee50d04e5691fa08548ef40e26,
title = "MicroRNAs in cardiometabolic disease",
abstract = "Defects in homeostatic regulation of cholesterol and fatty acids are associated with major cardiometabolic risk factors that are prevalent in type 2 diabetes and atherosclerotic cardiovascular disease. Regulatory input is found at many levels; however, recent findings have revealed pivotal roles for small non-coding RNAs (microRNAs) of the endogenous RNA interference pathway in post-transcriptional control of major regulatory mechanisms underpinning cholesterol and energy homeostasis. In addition, aberrant expression of microRNAs has been implicated in marked pathophysiologic events contributing to the progression and development of atherosclerosis, including loss of endothelial integrity, vascular smooth muscle cell proliferation, neointimal hyperplasia, and foam cell formation. This review surveys the impact of microRNA-mediated regulation in biological processes governing the cholesterol/lipoprotein metabolism, fatty acid β-oxidation (eg by miR-122 and miR-33), and endothelial dysfunction related to atherosclerosis. Given the current advances in microRNA-based technologies, the clinical potential of microRNAs as novel therapeutic targets is highlighted as new alternative strategies to ameliorate cardiometabolic diseases.",
keywords = "Atherosclerosis, Cholesterol, Fatty acids, Metabolism, microRNAs",
author = "Hani Najafi",
year = "2011",
month = "6",
doi = "10.1007/s11883-011-0179-y",
language = "English",
volume = "13",
pages = "202--207",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - MicroRNAs in cardiometabolic disease

AU - Najafi, Hani

PY - 2011/6

Y1 - 2011/6

N2 - Defects in homeostatic regulation of cholesterol and fatty acids are associated with major cardiometabolic risk factors that are prevalent in type 2 diabetes and atherosclerotic cardiovascular disease. Regulatory input is found at many levels; however, recent findings have revealed pivotal roles for small non-coding RNAs (microRNAs) of the endogenous RNA interference pathway in post-transcriptional control of major regulatory mechanisms underpinning cholesterol and energy homeostasis. In addition, aberrant expression of microRNAs has been implicated in marked pathophysiologic events contributing to the progression and development of atherosclerosis, including loss of endothelial integrity, vascular smooth muscle cell proliferation, neointimal hyperplasia, and foam cell formation. This review surveys the impact of microRNA-mediated regulation in biological processes governing the cholesterol/lipoprotein metabolism, fatty acid β-oxidation (eg by miR-122 and miR-33), and endothelial dysfunction related to atherosclerosis. Given the current advances in microRNA-based technologies, the clinical potential of microRNAs as novel therapeutic targets is highlighted as new alternative strategies to ameliorate cardiometabolic diseases.

AB - Defects in homeostatic regulation of cholesterol and fatty acids are associated with major cardiometabolic risk factors that are prevalent in type 2 diabetes and atherosclerotic cardiovascular disease. Regulatory input is found at many levels; however, recent findings have revealed pivotal roles for small non-coding RNAs (microRNAs) of the endogenous RNA interference pathway in post-transcriptional control of major regulatory mechanisms underpinning cholesterol and energy homeostasis. In addition, aberrant expression of microRNAs has been implicated in marked pathophysiologic events contributing to the progression and development of atherosclerosis, including loss of endothelial integrity, vascular smooth muscle cell proliferation, neointimal hyperplasia, and foam cell formation. This review surveys the impact of microRNA-mediated regulation in biological processes governing the cholesterol/lipoprotein metabolism, fatty acid β-oxidation (eg by miR-122 and miR-33), and endothelial dysfunction related to atherosclerosis. Given the current advances in microRNA-based technologies, the clinical potential of microRNAs as novel therapeutic targets is highlighted as new alternative strategies to ameliorate cardiometabolic diseases.

KW - Atherosclerosis

KW - Cholesterol

KW - Fatty acids

KW - Metabolism

KW - microRNAs

UR - http://www.scopus.com/inward/record.url?scp=79955879415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955879415&partnerID=8YFLogxK

U2 - 10.1007/s11883-011-0179-y

DO - 10.1007/s11883-011-0179-y

M3 - Review article

C2 - 21461683

AN - SCOPUS:79955879415

VL - 13

SP - 202

EP - 207

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 3

ER -